GHK-Cu

Mechanism of action

GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine (GHK), a naturally occurring peptide detectable in human plasma, saliva, and urine. The complex forms via coordination of Cu²⁺ to the imidazole nitrogen of histidine and the N-terminal amine, creating a square-planar or distorted square-planar geometry with a stability constant sufficiently high to enable transdermal copper delivery without generating free radical toxicity from labile copper ions. The principal mechanism by which GHK-Cu influences biology is copper delivery to cuproenzymes. Copper is an essential cofactor for lysyl oxidase — the enzyme responsible for cross-linking collagen and elastin fibres in the extracellular matrix. GHK-Cu-mediated enhancement of lysyl-oxidase activity therefore directly promotes the deposition of structurally competent fibrous matrix in wounded and remodelling tissues. It also activates superoxide dismutase (SOD), the main intracellular antioxidant enzyme. Both mechanisms converge to explain the pro-regenerative and anti-oxidative phenotype observed in GHK-Cu-treated dermal fibroblast cultures. Loren Pickart and colleagues performed genome-wide microarray analysis on human fibroblasts and identified more than 4,000 genes modulated by more than 50% upon GHK-Cu exposure. Notably, this included upregulation of DNA-repair gene networks (BRCA1, BRCA2), antioxidant defences, and tissue-remodelling proteases (MMP-2, MMP-9) alongside their inhibitors (TIMP-1, TIMP-2), suggesting a coordinated remodelling — rather than simply a pro-synthetic — transcriptional programme. Hair-follicle effects are attributed to stimulation of stem-cell differentiation in dermal papilla cells, upregulation of Wnt/β-catenin signalling, and local angiogenesis promotion. Research in alopecia models has demonstrated enlarged follicle diameter, increased anagen duration, and improved hair-shaft tensile strength, although clinical trials are limited. Anti-fibrotic effects have been demonstrated in pulmonary and hepatic fibrosis models, where GHK-Cu reduces TGF-β1-driven Smad phosphorylation and suppresses myofibroblast differentiation. This separates GHK-Cu mechanistically from many collagen-stimulating compounds that simultaneously increase fibrosis risk — GHK-Cu appears to favour mature, organised collagen deposition while attenuating pathological scar formation.

Genome-wide microarray analysis identified more than 4,000 genes modulated by more than 50% in GHK-Cu-treated human dermal fibroblasts, including DNA-repair, antioxidant, and tissue-remodelling networks — a transcriptional breadth that is exceptional for a synthetic tripeptide (Pickart L. et al., ScientificWorldJournal, 2010).

— Notable finding

Research history

The peptide GHK was discovered by Loren Pickart in 1973 while studying a plasma factor that caused old hepatocytes — whose synthetic capacity had declined with age — to behave more like young hepatocytes in mixed-culture experiments. This led to characterisation of GHK as an endogenous 'tissue-repair signal' whose plasma concentration falls sharply with advancing age (from approximately 200 ng/mL in young adults to around 80 ng/mL in older individuals), a decline Pickart proposed as a contributor to age-related impairment of wound healing. The copper-bound form, GHK-Cu, entered cosmetic dermatology in the 1980s and 1990s as a topical additive in anti-ageing and wound-care formulations. ProCyte Corporation was among the early commercial developers, and GHK-Cu was evaluated in clinical wound-care studies in the late 1980s and early 1990s with promising but commercially unpursued results. The genomic era reinvigorated interest in GHK-Cu when Pickart and colleagues published microarray data demonstrating the scale of its transcriptional effects. Subsequent work has expanded the potential application areas to include pulmonary fibrosis, neurodegeneration, and cancer-suppressor gene reactivation, though most of this work remains in cell-culture or small-animal stages. The cosmetic-ingredient designation 'Copper Tripeptide-1' is the INCI name used in commercial skin-care products sold throughout Europe and the UK.

Reported research-model dose ranges

The ranges below are taken from published pre-clinical literature. They do not constitute a dosing recommendation for human use.

Summarised studies

Safety profile

Topical GHK-Cu has an extensive safety record as a cosmetic ingredient at concentrations typically ranging from 0.05% to 0.5% weight-per-volume in marketed products. At these concentrations, adverse effects are rare; mild transient erythema and occasional contact sensitisation have been reported in patch-test literature, but serious cutaneous adverse events have not been documented. In-vitro and small-animal studies of injectable preparations have not identified acute organ toxicity. The critical concern with copper-containing compounds is the potential for copper overload at supraphysiological concentrations — free ionic copper is pro-oxidant and cytotoxic. GHK-Cu at physiologically relevant concentrations does not appear to liberate significant free copper; however, at high doses or with compromised endogenous copper metabolism (e.g. Wilson's disease), caution is warranted. Systemic long-term safety data for parenteral or high-dose GHK-Cu are absent. Researchers planning systemic animal studies should pilot-test doses and monitor hepatic copper accumulation. For topical laboratory preparations, standard cosmetic-grade safety testing (repeat-insult patch testing, phototoxicity) is relevant to any formulation intended for prolonged skin contact. Sterility and endotoxin testing apply to any injectable research preparation.

UK regulatory status

GHK-Cu (listed under the INCI name Copper Tripeptide-1) is a legally permitted cosmetic ingredient in the United Kingdom, regulated under the UK Cosmetic Products Regulation (Retained Regulation (EC) 1223/2009 as amended). There is no specific restriction or concentration limit on GHK-Cu in cosmetic formulations, provided the product overall meets the general safety obligation and is manufactured to appropriate standards. As a research peptide for injectable or systemic experimental use, GHK-Cu is not licensed as a medicine by the MHRA. No marketing authorisation, investigational product certificate, or orphan designation is held by any sponsor in the UK for therapeutic GHK-Cu. Researchers conducting animal studies with GHK-Cu in the UK should hold appropriate Home Office project licences under the Animals (Scientific Procedures) Act 1986 (ASPA). GHK-Cu is not currently listed on the WADA Prohibited List, and its primary applications (topical cosmetic, dermatological research) do not intersect with anti-doping concerns. However, any systemic research administration in an athlete context should be reviewed against the current Prohibited List for substances not specifically named but potentially covered by class-based prohibitions.

Frequently asked questions